Understanding APC - malecare.org

PSA Decline is a Potential Biomarker for Identifying Early Resistance to Zytiga and Xtandi In Men Who are Post Chemotherapy*

Abiraterone Acetate (Zytiga) and enzalutamide (Xtandi) are the newest generation hormonal agents. They both have demonstrated a survival advantage in men with castrate resistant prostate cancer (CRPC) who have already been treated with docetaxel (chemotherapy). Unfortunately all men who are responsive to both of these drugs eventually become resistant. Some men are subject to early [...]

By Malecare|2017-10-19T10:48:08-04:00July 9th, 2014|abiraterone acetate, Advanced Prostate Cancer, biomarkers, Drugs & Treatments, enzalutamide, General Information, Uncategorized, Understanding APC, Xtandi, Zytiga|0 Comments

Defaulting Cancer Treatment Is Associated with Psychological Distress and A Desire for Psychological Support*

Sometimes some of us just simply decide that we will not start any treatment or continue a treatment protocol simply because we don’t want to have treatment. This type of decision is different from our deciding that a specific treatment has too many side effects for the potential upside it might provide. Researchers set out [...]

By Malecare|2014-07-08T09:56:48-04:00July 8th, 2014|Advanced Prostate Cancer, Drugs & Treatments, General Information, How We Live, mental health, Research, Uncategorized, Understanding APC|0 Comments

Efficacy of Long-Term Treatment of > 5-10 Years with the LHRH Drug Leuprorelin (Lupron)

Popular culture tells us that primary androgen deprivation therapy with leuprorelin acetate (Lupron) will not work for longer than two years! This is a significant and very problematic statement given that all of us with metastatic prostate cancer rely on delaying the move to any other treatments, especially given their cost to the quality of [...]

By Malecare|2014-06-30T16:49:05-04:00June 30th, 2014|ADT, Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, Germany, Hormone Therapy, Uncategorized, Understanding APC|2 Comments

Looking Forward Towards the Future – Zytiga or Xtandi First After Provenge

What will happen when enzalutamide (Xtandi) is approved for use in advanced prostate cancer in the disease stage prior to chemotherapy (that is if it is approved)? Already occupying this space and already approved by the FDA is both Provenge and abiraterone (Zytiga). Where will Xtandi fit in? Until we have a lot more data, [...]

By Malecare|2017-10-19T10:48:08-04:00June 27th, 2014|2nd line hormone therapy, abiraterone acetate, Advanced Prostate Cancer, Drugs & Treatments, enzalutamide, Provenge, Uncategorized, Understanding APC, Xtandi, Zytiga|8 Comments

Limiting Lower Urinary Tract Symptoms in Men with Prostate Cancer

Prostate cancer is commonly associated with lower urinary tract symptoms (LUTS). The use of GnRH agonists or antagonists (first line ADT) is widely used as the primary treatment for advanced prostate cancer (pc) and/or to reduce prostate volume (TPV). It is thought that the ADT contributes to the development of LUTS. Researchers pooled multiple other [...]

By Malecare|2020-02-04T10:11:41-05:00June 26th, 2014|ADT, Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, Firmagon (degarelix), Hormone Therapy, Uncategorized, Understanding APC, United Kingdom - England, Northern Ireland, Scotland & Wales|0 Comments